SCHEMBL1797549

SCHEMBL1797549

Clc1ccc(/C=C/c2nc3cc(-c4ccccc4)ccc3[nH]2)c(Cl)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 7/20 0.72
▸ RAB9A P51151 7/20 0.72
▸ MAPT P10636 6/20 0.72
▸ KMT2A Q03164 6/20 0.72
▸ KDM4E B2RXH2 6/20 0.72
▸ ALDH1A1 P00352 6/20 0.72
▸ HPGD P15428 5/20 0.72
▸ SMN1; SMN2 Q16637 5/20 0.72
▸ MEN1 O00255 5/20 0.72
▸ LMNA P02545 4/20 0.72
▸ GAA P10253 3/20 0.72
▸ PKM P14618 3/20 0.72
▸ GLA P06280 2/20 0.72
▸ HTT P42858 2/20 0.72
▸ ALPL P05186 1/20 0.72
▸ ALPG P10696 1/20 0.72
▸ TUBB4A P04350 2/20 0.46
▸ TUBB P07437 2/20 0.46
▸ TUBA3C P0DPH7 2/20 0.46
▸ TUBA1B P68363 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1797554 1.00 NPC1 (0.72) NPC1RAB9AMAPTKMT2AKDM4E
SCHEMBL1796256 0.85 NPC1 (0.68) NPC1RAB9AMAPTKMT2AKDM4E
SCHEMBL1796258 0.85 NPC1 (0.68) NPC1RAB9AMAPTKMT2AKDM4E
SCHEMBL7808579 0.84 NPC1 (1.00) NPC1RAB9AMAPTKMT2AKDM4E
SCHEMBL1798187 0.81 TRPV1 (0.62) NPC1RAB9AMAPTKMT2AKDM4E
SCHEMBL1798183 0.81 TRPV1 (0.62) NPC1RAB9AMAPTKMT2AKDM4E
SCHEMBL1798200 0.80 NPC1 (0.51) NPC1RAB9AMAPTKMT2AKDM4E
SCHEMBL1798202 0.80 NPC1 (0.51) NPC1RAB9AMAPTKMT2AKDM4E
SCHEMBL1797039 0.78 MAPT (0.55) NPC1RAB9AMAPTKMT2AKDM4E
SCHEMBL1797042 0.78 MAPT (0.55) NPC1RAB9AMAPTKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190364-A1 BENZIMIDAZOLE MODULATORS OF VR1 JANSSEN PHARMACEUTICA N.V. (BE) 2011-08-04 — — US disclosed
US-20110190344-A1 BENZIMIDAZOLE MODULATORS OF VR1 JANSSEN PHARMACEUTICA N.V. (BE) 2011-08-04 — — US disclosed
US-7951829-B2 Benzimidazole modulators of VR1 JANSSEN PHARMACEUTICA NV (BE) 2011-05-31 — — US disclosed
US-20070259936-A1 Benzimidazole Modulators of VR1 JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190364-A1 BENZIMIDAZOLE MODULATORS OF VR1 VRK1, VRK2, VIL1 NPC1 750/4885RAB9A 3985/4885MAPT 4694/4885
US-20070259936-A1 Benzimidazole Modulators of VR1 VRK1, VRK2, VIL1 NPC1 750/4885RAB9A 3985/4885MAPT 4694/4885
US-20110190344-A1 BENZIMIDAZOLE MODULATORS OF VR1 VRK1, VRK2, VIL1 NPC1 750/4885RAB9A 3985/4885MAPT 4694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback